Evogene’s Q2 Revenues Rise, Loss Trimmed

Aug 31, 2007

Agricultural biotech firm Evogene announced this week that its second quarter revenues rose to $129,000 from $10,500 in the second quarter last year.

The Israeli firm posted a net loss of $738,000, or $.05 per share, for the three months ended June 30, compared with a net loss of $836,000, or $.06 per share, for the comparable period a year ago.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

Push for Predictive Genetic Tests

Matt Hancock, the UK health secretary, is calling for the swift rollout of predictive genetic tests, the Guardian reports.

Gene-Editing Registry Proposed

A WHO panel is calling for a global registry of human germline gene-editing projects, according to Stat News.

Sneaking Out of the Lab

Vox writes that lab mishaps involving pathogens are quite common.

This Week in Genome Biology

In Genome Biology this week: analysis of wild and cultivated peach genomes, Hi-C-based pipeline for assembling microbial genomes from metagenomic data, and more.

Menu